131 related articles for article (PubMed ID: 26049698)
1. Challenges of Pancreatic Cancer.
Dimastromatteo J; Houghton JL; Lewis JS; Kelly KA
Cancer J; 2015; 21(3):188-93. PubMed ID: 26049698
[TBL] [Abstract][Full Text] [Related]
2. The Quest for an Effective Treatment for an Intractable Cancer: Established and Novel Therapies for Pancreatic Adenocarcinoma.
Quinn BA; Lee NA; Kegelman TP; Bhoopathi P; Emdad L; Das SK; Pellecchia M; Sarkar D; Fisher PB
Adv Cancer Res; 2015; 127():283-306. PubMed ID: 26093904
[TBL] [Abstract][Full Text] [Related]
3. FoxO1-negative cells are cancer stem-like cells in pancreatic ductal adenocarcinoma.
Song W; Li Q; Wang L; Huang W; Wang L
Sci Rep; 2015 Jun; 5():10081. PubMed ID: 26068418
[TBL] [Abstract][Full Text] [Related]
4. Genomic expression profiling and bioinformatics analysis of pancreatic cancer.
Han DY; Fu D; Xi H; Li QY; Feng LJ; Zhang W; Ji G; Xiao JC; Wei Q
Mol Med Rep; 2015 Sep; 12(3):4133-4140. PubMed ID: 26062681
[TBL] [Abstract][Full Text] [Related]
5. Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles.
Blanco VM; Latif T; Chu Z; Qi X
Transl Oncol; 2015 Jun; 8(3):196-203. PubMed ID: 26055177
[TBL] [Abstract][Full Text] [Related]
6. [Pancreatic adenocarcinoma: 10 years of progress].
Hammel P; Neuzillet C; Bendaoud S; Lekhal C; de Mestier L; Hentic O
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S62-71. PubMed ID: 26118879
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability.
Nanda RH; El-Rayes B; Maithel SK; Landry J
J Surg Oncol; 2015 Jun; 111(8):1028-34. PubMed ID: 26073887
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of 10-Year Survivors of Pancreatic Ductal Adenocarcinoma.
Paniccia A; Hosokawa P; Henderson W; Schulick RD; Edil BH; McCarter MD; Gajdos C
JAMA Surg; 2015 Aug; 150(8):701-10. PubMed ID: 26062046
[TBL] [Abstract][Full Text] [Related]
9. Advances in Biomedical Imaging, Bioengineering, and Related Technologies for the Development of Biomarkers of Pancreatic Disease: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases and National Institute of Biomedical Imaging and Bioengineering Workshop.
Kelly KA; Hollingsworth MA; Brand RE; Liu CH; Singh VK; Srivastava S; Wasan AD; Yadav D; Andersen DK
Pancreas; 2015 Nov; 44(8):1185-94. PubMed ID: 26465948
[TBL] [Abstract][Full Text] [Related]
10. CXCR4--A Prognostic and Clinicopathological Biomarker for Pancreatic Ductal Adenocarcinoma: A Meta-Analysis.
Krieg A; Riemer JC; Telan LA; Gabbert HE; Knoefel WT
PLoS One; 2015; 10(6):e0130192. PubMed ID: 26091099
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic cancer stromal biology and therapy.
Xie D; Xie K
Genes Dis; 2015 Jun; 2(2):133-143. PubMed ID: 26114155
[TBL] [Abstract][Full Text] [Related]
12. When Medical News Comes from Press Releases-A Case Study of Pancreatic Cancer and Processed Meat.
Taylor JW; Long M; Ashley E; Denning A; Gout B; Hansen K; Huws T; Jennings L; Quinn S; Sarkies P; Wojtowicz A; Newton PM
PLoS One; 2015; 10(6):e0127848. PubMed ID: 26083640
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer.
Makielski RJ; Lubner SJ; Mulkerin DL; Traynor AM; Groteluschen D; Eickhoff J; LoConte NK
Cancer Chemother Pharmacol; 2015 Aug; 76(2):317-23. PubMed ID: 26068189
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of the gene expression profiles for protein coding and non-coding RNAs of pancreatic ductal adenocarcinomas.
Gutiérrez ML; Corchete L; Teodosio C; Sarasquete ME; del Mar Abad M; Iglesias M; Esteban C; Sayagues JM; Orfao A; Muñoz-Bellvis L
Oncotarget; 2015 Aug; 6(22):19070-86. PubMed ID: 26053098
[TBL] [Abstract][Full Text] [Related]
15. The roles of lncRNAs and miRNAs in pancreatic cancer: a focus on cancer development and progression and their roles as potential biomarkers.
Jafari S; Motedayyen H; Javadi P; Jamali K; Moradi Hasan-Abad A; Atapour A; Sarab GA
Front Oncol; 2024; 14():1355064. PubMed ID: 38559560
[TBL] [Abstract][Full Text] [Related]
16. Drug Delivery Strategies for the Treatment of Pancreatic Cancer.
Olajubutu O; Ogundipe OD; Adebayo A; Adesina SK
Pharmaceutics; 2023 Apr; 15(5):. PubMed ID: 37242560
[TBL] [Abstract][Full Text] [Related]
17. C9orf16 represents the aberrant genetic programs and drives the progression of PDAC.
Chen X; Zhang H; Xiao B
BMC Cancer; 2022 Oct; 22(1):1102. PubMed ID: 36307773
[TBL] [Abstract][Full Text] [Related]
18. Imaging Modalities for Early Detection of Pancreatic Cancer: Current State and Future Research Opportunities.
Farr KP; Moses D; Haghighi KS; Phillips PA; Hillenbrand CM; Chua BH
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626142
[TBL] [Abstract][Full Text] [Related]
19. Modeling the mechanical stiffness of pancreatic ductal adenocarcinoma.
Kpeglo D; Hughes MDG; Dougan L; Haddrick M; Knowles MA; Evans SD; Peyman SA
Matrix Biol Plus; 2022 Jun; 14():100109. PubMed ID: 35399702
[TBL] [Abstract][Full Text] [Related]
20. ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma.
Henry KE; Mack KN; Nagle VL; Cornejo M; Michel AO; Fox IL; Davydova M; Dilling TR; Pillarsetty N; Lewis JS
Mol Cancer Ther; 2021 Oct; 20(10):2026-2034. PubMed ID: 34349003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
